Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Hasła przedmiotowe:

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Hasła przedmiotowe:

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Hasła przedmiotowe:

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Hasła przedmiotowe:

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma od Evangeline R. Jackson (15558808)

Hasła przedmiotowe:

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Hasła przedmiotowe:

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Hasła przedmiotowe:

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma od Anne-Florence Blandin (15056366)

Hasła przedmiotowe:

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma od Srivandana Akshintala (16610490)

Hasła przedmiotowe: